GANX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 16:00):

Stats
Today's Volume	77 894.00
Average Volume	161 308
Market Cap	51.09M
EPS	$0 ( 2024-03-28 )
Next earnings date	( $-0.280 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.840
ATR14	$0.0280 (0.89%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Mack Gene	Buy	200 000	Employee Stock Option (right to buy)
2024-04-05	Mack Gene	Buy	0
2024-03-28	Riley Jeffrey Scott	Buy	30 000	Common Stock
2024-03-26	Alder Matthias	Sell	18 750	Restricted Stock Units
2024-03-26	Alder Matthias	Buy	637	Common Stock

INSIDER POWER
86.88
Last 62 transactions
Buy: 1 996 906 \| Sell: 408 942

Volume Correlation

Long: -0.08 (neutral)

Short: -0.16 (neutral)

Signal:(39.09) Neutral

Gain Therapeutics, Inc. Correlation

10 Most Positive Correlations
EMLD	0.95
ARRW	0.946
FTAA	0.937
OXAC	0.934
BCOR	0.933
HCVI	0.933
ARDX	0.932
MSAC	0.931
ADAL	0.93
FWAC	0.93

10 Most Negative Correlations
BFC	-0.941
VORB	-0.926
BMRA	-0.923
ZSAN	-0.922
ORPH	-0.922
YJ	-0.92
EVLO	-0.92
CUTR	-0.919
HALO	-0.919
GRIN	-0.919

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Gain Therapeutics, Inc. Correlation - Currency/Commodity

-0.72
( moderate negative )

-0.79
( moderate negative )

0.00
( neutral )

-0.69
( moderate negative )

0.40
( neutral )

0.79
( moderate )

Gain Therapeutics, Inc. Financials

Annual	2023
Revenue:	$55 180.00
Gross Profit:	$-25 202.00 (-45.67 %)
EPS:	$-1.710

Q4	2023
Revenue:	$0
Gross Profit:	$-23 589.00 (0.00 %)
EPS:	$-0.290

Q3	2023
Revenue:	$0
Gross Profit:	$-20 509.00 (0.00 %)
EPS:	$-0.370

Q2	2023
Revenue:	$0
Gross Profit:	$-20 239.00 (0.00 %)
EPS:	$-0.620

Financial Reports:

No articles found.

Gain Therapeutics, Inc.

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.